ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 33 for:    FSHD

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients With Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02239224
Recruitment Status : Completed
First Posted : September 12, 2014
Last Update Posted : July 11, 2017
Sponsor:
Information provided by (Responsible Party):
aTyr Pharma, Inc.

Brief Summary:
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult patients with molecularly defined genetic muscular dystrophies

Condition or disease Intervention/treatment Phase
Facioscapulohumeral Muscular Dystrophy (FSHD) Biological: Placebo Biological: ATYR1940 Phase 1 Phase 2

Detailed Description:

Study ATYR1940-C-002 is a multi-national, multi-center, double-blind, randomized, placebo-controlled, ascending dose study designed to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamic effects of ATYR1940 in patients with FSHD. Up to 44 patients are planned to be enrolled at multiple study centers in the U.S. and Europe; the actual number of patients enrolled will depend on the number of cohorts initiated.

Patients will be screened for study eligibility during the Screening period within 3 weeks before Baseline (i.e., Day 1, the first day of Study Drug administration). Eligible patients, based on Screening assessments, will be randomly assigned to treatment with ATYR1940 or placebo. Patients who are randomized are considered to be enrolled in the study.

After enrollment, patients will enter the 1-week single-blind placebo period during which all patients will receive a single 30-minute IV infusion of placebo. Thereafter, patients will enter the double-blind treatment period and will receive 30-minute IV infusions of Study Drug (ATYR1940 or placebo) according to their random treatment assignment.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Biological Activity of ATYR1940 in Adult Patients With Molecularly Defined Genetic Muscular Dystrophies
Actual Study Start Date : August 2014
Actual Primary Completion Date : December 21, 2015
Actual Study Completion Date : December 21, 2015


Arm Intervention/treatment
Experimental: ATYR1940
ATYR1940 : IV; 0.3, 1.0, or 3.0 mg/kg; once a week; Up to 12 weeks
Biological: ATYR1940
Patients will enter the double-blind treatment period and will receive 30-minute IV infusions of ATYR1940 according to their random treatment assignment.

Placebo Comparator: Placebo
Placebo: IV; 0.3, 1.0, or 3.0 mg/kg; once a week; Up to 12 weeks
Biological: Placebo
Patients will enter the double-blind treatment period and will receive 30-minute IV infusions of Placebo according to their random treatment assignment.




Primary Outcome Measures :
  1. Safety and tolerability of ATYR1940 in adult patients with molecularly defined genetic muscular dystrophies [ Time Frame: Up to 1 month ]
    Change from Baseline of physical examination

  2. Safety and tolerability of ATYR1940 in adult patients with molecularly defined genetic muscular dystrophies [ Time Frame: Up to 1 month ]
    Change from Baseline in vital sign measurements and pulmonary evaluation

  3. Safety and tolerability of ATYR1940 in adult patients with molecularly defined genetic muscular dystrophies [ Time Frame: Up to 1 month ]
    Incidences of Adverse Events (AEs), including serious and severe AEs

  4. Safety and tolerability of ATYR1940 in adult patients with molecularly defined genetic muscular dystrophies [ Time Frame: Up to 1 month ]
    Change from Baseline in safety laboratory test results


Secondary Outcome Measures :
  1. Pharmacokinetics of ATYR1940 in adult patients with molecularly defined genetic muscular dystrophies [ Time Frame: Up to 1 month ]
    Cmax: Observed maximum serum concentration

  2. Pharmacokinetics of ATYR1940 in adult patients with molecularly defined genetic muscular dystrophies [ Time Frame: Up to 1 month ]
    Tmax: Time to attain maximum serum concentration

  3. Pharmacokinetics of ATYR1940 in adult patients with molecularly defined genetic muscular dystrophies [ Time Frame: Up to 1 month ]
    T 1/2: Elimination half-life

  4. Pharmacokinetics of ATYR1940 in adult patients with molecularly defined genetic muscular dystrophies [ Time Frame: Up to 1 month ]
    AUC 0-t: Area under the serum concentration-time curve up to time t



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is a male or female aged 18 to 65 years, inclusive.
  • Patient has an established, genetically-confirmed, diagnosis of facioscapulohumeral dystrophy with clinical findings meeting existing criteria.
  • Patient has provided written informed consent after the nature of the study has been explained and prior to the performance of any research-related procedures.
  • Patient is, in the Investigator's opinion, willing and able to comply with all study procedures.
  • Cohorts ≥2 only: Patient has imaging findings meeting defined criteria for muscle inflammation in at least 1 skeletal muscle

Exclusion Criteria:

  • Patient is currently receiving treatment with an immunomodulatory agent or has a history of such treatment, including targeted biological therapies (e.g., etanercept, omalizumab) within the 3 months before Baseline; corticosteroids within 4 weeks before Baseline; or high-dose non-steroidal anti-inflammatory agents (NSAIDs) within 2 weeks before Baseline.
  • Patient is currently receiving curcumin or albuterol or requires such treatment during study participation.
  • Patient has evidence of an alternative diagnosis other than FSHD, based on prior muscle biopsy or genetic test findings.
  • Patient has a presumptive diagnosis of FSHD, based on clinical assessment, but does not yet have genetic confirmation of the diagnosis.
  • Patient has a severe retinopathy.
  • Patient has a history of obstructive or restrictive lung disease (including interstitial lung disease, pulmonary fibrosis, or asthma), or evidence for interstitial lung disease on Screening chest radiograph.
  • Patient has a history of anti-synthetase syndrome, prior Jo-1 antibody (Ab)-positivity, or has a positive or equivocally positive Jo-1 Ab test result during Screening.
  • Patient has acute or clinically relevant Epstein-Barr virus or cytomegalovirus infection or re-activation.
  • Patient has a chronic infection such as hepatitis B virus, hepatitis C virus, or human immunodeficiency virus or a history of tuberculosis.
  • Patient has received a vaccination within 8 weeks before Baseline or vaccination is planned during study participation.
  • Patient has symptomatic cardiomyopathy or severe cardiac arrhythmia that may, in the Investigator's opinion, limit the patient's ability to complete the study protocol.
  • Patient has anemia (as defined for patient's age and gender by local laboratory range).
  • Patient has gamma-glutamyl transferase (GGT) or serum creatinine levels >2 × the upper limit of normal (ULN).
  • Patient has abnormal baseline findings, medical condition(s), or laboratory findings that, in the Investigator's opinion, might jeopardize patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
  • Patient has evidence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, metabolic, dermatological, or gastrointestinal disease, or has a condition that requires immediate surgical intervention or other treatment or may not allow safe participation.
  • Patient has used any investigational product or device (other than a mobility assistance device) within 30 days before Baseline.
  • Patient has received a product intended to enhance muscle growth within 30 days before Baseline.
  • Patient underwent muscle biopsy within 30 days before Baseline.
  • Patient initiated treatment with a statin or had a significant adjustment to their statin regimen within 3 months before Baseline. (Stable, chronic statin use is permissible.)
  • Patient has received a product that putatively enhances muscle growth (e.g., insulin-like growth factor, growth hormone) or activity (e.g., Coenzyme A) on a chronic basis within 4 weeks before Baseline.
  • Patient is unwilling to abstain from strenuous physical activity for 24 hours prior to each study center visit.
  • Patient previously received ATYR1940.
  • If female and of childbearing potential (premenopausal and not surgically sterile), patient has a positive pregnancy test at Screening or is unwilling to use contraception from the time of Screening through 1 -month after the last Study Drug dose. Acceptable methods of birth control include abstinence, barrier methods, hormones, or intra-uterine device.
  • If male, patient is unwilling to use a condom plus spermicide during sexual intercourse from the time of Screening through 1 -month after the last Study Drug dose.
  • Cohorts ≥2 only: Patient has a known contraindication for MRI assessments (e.g., metal prosthesis or pacemaker) as per local site MRI protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02239224


Locations
United States, New York
aTyr Pharma Investigative Site
Rochester, New York, United States, 14642
United States, Ohio
aTyr Pharma Investigative Site
Columbus, Ohio, United States, 43210
France
aTyr Pharma Investigative Site
Marseille, France
Italy
aTyr Pharma Investigative Site
Rome, Italy
Netherlands
aTyr Pharma Investigative Site
Nijmegen, Netherlands
Sponsors and Collaborators
aTyr Pharma, Inc.
Investigators
Study Director: Sanjay Shukla, MD aTyr Pharma

Responsible Party: aTyr Pharma, Inc.
ClinicalTrials.gov Identifier: NCT02239224     History of Changes
Other Study ID Numbers: ATYR1940-C-002
2014-001753-17 ( EudraCT Number )
First Posted: September 12, 2014    Key Record Dates
Last Update Posted: July 11, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by aTyr Pharma, Inc.:
FSHD

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn